Patient keeps a diary throughout study. Labs and physicals at screening and termination visits only. Patients are eligible for open label immediately upon completion of randomization. They receive a Morphelan dose equal to daily dose MSContin attained during stabilization. Morphelan is taken once daily, in the morning.
Open label is available for up to one year after entry.
Monthly visits are required with interim visits for titration as needed. Labs and physicals completed every two months. Medtronic Quality of Life Cancer patients entering this study are randomized to one of two groups. The first group will continue to receive therapy as would be expected. Patients in the second group receive a SynchroMed intrathecal pump.